Insulin Glargine vs Insulin Detemir
Clinical Comparison
Clinical Context
Both are long-acting basal insulin analogues recommended by NICE for type 1 and type 2 diabetes when basal insulin is needed. Insulin glargine is the most widely prescribed due to its reliable once-daily dosing. Insulin detemir is associated with less weight gain and may be preferred where this is a priority, though it often requires twice-daily dosing.
Drug Profiles
Insulin Glargine
Long-acting basal insulin analogue
Mechanism
Modified insulin that precipitates at physiological pH after subcutaneous injection, creating a depot that slowly dissolves, providing a flat, peakless insulin profile over ~24 hours
Indications
- Type 1 diabetes (basal component of basal-bolus regimen)
- Type 2 diabetes (when oral agents are insufficient)
Common Doses
Starting dose: 10 units OD or 0.2 units/kg/day; titrate based on fasting glucose. Available as U-100 and U-300 (Toujeo)
Route
Subcutaneous
Onset & Duration
Onset 1-2 hours; no pronounced peak; duration 20-26 hours (U-100) or up to 36 hours (U-300)
Insulin Detemir
Long-acting basal insulin analogue
Mechanism
Fatty acid (myristic acid) conjugated insulin that binds to albumin after injection, creating a slow-release buffer. Also self-associates at injection site, slowing absorption
Indications
- Type 1 diabetes (basal component)
- Type 2 diabetes (when oral agents insufficient)
Common Doses
Starting dose: 10 units OD or BD; titrate based on fasting glucose. Often requires BD dosing in type 1 diabetes
Route
Subcutaneous
Onset & Duration
Onset 1-2 hours; slight peak at 6-8 hours; duration 16-24 hours (dose-dependent)
Key Differences
| Category | Insulin Glargine | Insulin Detemir |
|---|---|---|
| Dosing frequency | Once daily (reliable 24-hour cover) | Often twice daily in type 1 diabetes (16-24 hour duration) |
| Weight gain | Moderate weight gain | Less weight gain than glargine |
| Absorption profile | Flat, peakless | Slight peak at 6-8 hours |
| Duration | 20-26 hours (U-100); up to 36 hours (U-300) | 16-24 hours (dose-dependent) |
| Mixing with other insulins | Cannot be mixed (acidic formulation) | More compatibility for mixing |
| Cost | Widely available as biosimilar — increasingly affordable | Generally similar cost |
Dosing frequency
Once daily (reliable 24-hour cover)
Often twice daily in type 1 diabetes (16-24 hour duration)
Weight gain
Moderate weight gain
Less weight gain than glargine
Absorption profile
Flat, peakless
Slight peak at 6-8 hours
Duration
20-26 hours (U-100); up to 36 hours (U-300)
16-24 hours (dose-dependent)
Mixing with other insulins
Cannot be mixed (acidic formulation)
More compatibility for mixing
Cost
Widely available as biosimilar — increasingly affordable
Generally similar cost
Key Advantages
Insulin Glargine
- Once-daily injection
- Flat, peakless profile — lower nocturnal hypoglycaemia
- Consistent 24-hour coverage
- U-300 (Toujeo) option for higher dose requirements with extended duration
Insulin Detemir
- Less weight gain than glargine and NPH insulin
- Can be mixed with rapid-acting insulins in some protocols
- Albumin binding provides predictable absorption
- Lower within-patient variability in absorption
Key Cautions
Insulin Glargine
- Cannot be mixed with other insulins (acidic pH)
- Injection site lipohypertrophy with repeated use at same site
- Weight gain
- Hypoglycaemia (less nocturnal than NPH insulin)
- Must not be given IV
Insulin Detemir
- Often requires twice-daily dosing (especially in type 1 diabetes)
- Dose-dependent duration — shorter at lower doses
- Weight gain (less than glargine but still occurs)
- Injection site reactions
- Must not be given IV
Clinical Verdict
Insulin glargine is the standard first-choice basal insulin due to reliable once-daily dosing and true 24-hour coverage. Consider insulin detemir when weight gain is a primary concern, accepting that twice-daily dosing may be needed.
Medical Disclaimer: This comparison is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making prescribing decisions. Verify all drug information with current clinical guidelines (BNF, NICE, SmPCs).
Full monographs for Insulin Glargine & Insulin Detemir in the MedNext app
Complete dosing, interactions, contraindications, side effects, and more — covering 2,866 drugs with AI-powered search.
Download MedNext Formulary